This proof-of-concept.

Telatinib gets the potential to transformation the standard of treatment in this cancer indication.’ Added Wolf D. Busse, CEO and President of Action Biotech, ‘These data support the initiation of registration trials in advanced gastric cancers, keeping Telatinib on the right track to file for marketing approval in both Europe and america by 2014.’.. ACT Biotech reports positive interim data from Telatinib Phase 2 trial for advanced gastric cancer ACT Biotech Inc.A fresh government report implies that the rise in health care spending slowed for the second consecutive year. Meanwhile, medical health insurance premiums continue steadily to climb as employees pay an ever-growing share of the cost. Ray Suarez discusses what’s behind these changes with Susan Dentzer of Wellness Affairs .S. Health care spending this year 2010 grew at the second-slowest rate in 51 years, as individuals continuing to postpone hospitalizations, fill fewer drug prescriptions and avoid doctor visits in the aftermath of the Great Recession, monday according to a government report released. Medscape: Spending on Physician Solutions Continues to DECELERATE Probably the most dramatic deacclerations was seen in prescription drugs, where spending development went from 5.